Literature DB >> 3148147

Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients.

K K Midha1, E M Hawes, J W Hubbard, E D Korchinski, G McKay.   

Abstract

The single dose pharmacokinetics of fluphenazine (2 x 5 mg tablets, Prolixin) were studied in 21 drug free male psychiatric patients (12 black, 9 white). Plasma samples were harvested over a period of 48 h while the patients were on a strictly controlled diet. The results showed wide interpatient variations in all pharmacokinetic parameters including Cmax, AUC, apparent oral clearance, and elimination half-life. It was determined for each of these parameters that the geometric mean gave a better estimate of central tendency than the corresponding arithmetic mean and the distribution was skewed and leptokurtotic. There was no significant difference between blacks and whites in any pharmacokinetic parameter examined. Considerable variations and marked undulations in the elimination portion of the plasma concentration versus time profiles were evident, possibly indicating biliary recycling of the drug. These undulations made it difficult to determine elimination rate constants for several of the patients. Hydrolysis or plasma samples from one patient demonstrated that the conjugate(s) of fluphenazine was present in three to four times the concentration of the unchanged drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3148147     DOI: 10.1007/bf00177561

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Fluphenazine activity and antipsychotic response.

Authors:  R J Hitzemann; D L Garver; M Mavroidis; J Hirschowitz; F P Zemlan
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Fluphenazine, trifluoperazine and perphenazine in Vacutainers.

Authors:  K K Midha; J K Cooper; Y D Lapierre; J W Hubbard
Journal:  Can Med Assoc J       Date:  1981-02-01       Impact factor: 8.262

3.  Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.

Authors:  S R Marder; E M Hawes; T Van Putten; J W Hubbard; G McKay; J Mintz; P R May; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Therapeutic blood levels of fluphenazine: plasma or RBC determinations?

Authors:  M L Mavroidis; D R Kanter; J Hirschowitz; D L Garver
Journal:  Psychopharmacol Bull       Date:  1984

5.  Methods for study of fluphenazine kinetics in man.

Authors:  R Whelpton; S H Curry
Journal:  J Pharm Pharmacol       Date:  1976-12       Impact factor: 3.765

6.  Fluphenazine plasma levels and clinical response.

Authors:  M L Mavroidis; D R Kanter; J Hirschowitz; D L Garver
Journal:  J Clin Psychiatry       Date:  1984-09       Impact factor: 4.384

7.  Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol.

Authors:  K K Midha; B S Chakraborty; D A Ganes; E M Hawes; J W Hubbard; D L Keegan; E D Korchinski; G McKay
Journal:  J Clin Psychopharmacol       Date:  1989-04       Impact factor: 3.153

8.  Fluphenazine blood levels and clinical response.

Authors:  P Q Harris; M J Friedman; B M Cohen; T B Cooper
Journal:  Biol Psychiatry       Date:  1982-10       Impact factor: 13.382

9.  Fluphenazine pharmacokinetics and therapeutic response.

Authors:  M W Dysken; J I Javaid; S S Chang; C Schaffer; A Shahid; J M Davis
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.

Authors:  A C Altamura; S H Curry; S Montgomery; D H Wiles
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  5 in total

1.  Ethnic differences in the neuroleptic treatment of schizophrenia.

Authors:  P Ruiz; R V Varner; D R Small; B A Johnson
Journal:  Psychiatr Q       Date:  1999

2.  Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

Authors:  B M Cohen; T Tsuneizumi; R J Baldessarini; A Campbell; S M Babb
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Authors:  K K Midha; J W Hubbard; S R Marder; B D Marshall; T Van Putten
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

Review 4.  Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.

Authors:  G V Milton; M W Jann
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

Review 5.  Pharmacokinetic optimisation of the treatment of psychosis.

Authors:  A E Balant-Gorgia; L P Balant; A Andreoli
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.